The Technical Analyst
Gritstone Oncology Inc [GRTS]
Exchange: NASDAQ Sector: Healthcare Industry: Biotechnology
Gritstone Oncology Inc Price, Forecast, Insider, Ratings, Fundamentals & Signals
Current Signal: BUY (auto-tracking)
-0.20% $0.744
America/New_York / 18 apr 2024 @ 16:00
| FUNDAMENTALS | |
|---|---|
| MarketCap: | 79.13 mill |
| EPS: | -1.200 |
| P/E: | -0.620 |
| Earnings Date: | May 09, 2024 |
| SharesOutstanding: | 106.40 mill |
| Avg Daily Volume: | 2.91 mill |
| RATING 2024-04-18 |
|---|
| B |
| Neutral |
| RATINGS | ||
|---|---|---|
| Rating CashFlow: | Strong Sell | |
| Return On Equity: | Strong Sell | |
| Return On Asset: | Sell | |
| DE: | Strong Buy | |
| P/E: | Neutral | |
| Price To Book: | Buy |
| QUARTER GROWTHS | ||||||
|---|---|---|---|---|---|---|
| 3/22 | 4/22 | 1/23 | 2/23 | 3/23 | 4/23 | |
| Revenue | ||||||
| Gr.Profit | ||||||
| Ebit | ||||||
| Asset | ||||||
| Debt |
| PE RATIO: COMPANY / SECTOR |
|---|
| 0.00x |
| Company: PE -0.620 | sector: PE -3.05 |
| PE RATIO: COMPANY / INDUSTRY |
|---|
| -0.11x |
| Company: PE -0.620 | industry: PE 5.88 |
| DISCOUNTED CASH FLOW VALUE |
|---|
|
$-0.554 (-174.44%) $-1.297 |
| Date: 2024-04-18 |
| Expected Trading Range (DAY) |
|---|
|
$ 0.477 - 1.009 ( +/- 35.82%) |
| ATR Model: 14 days |
Insider Trading
| Date | Person | Action | Amount | type |
|---|---|---|---|---|
| 2024-02-01 | Hawryluk Matthew | Buy | 35 000 | Common Stock |
| 2024-02-01 | Hawryluk Matthew | Buy | 180 000 | Stock Option (Right to Buy) |
| 2024-02-01 | Jones Erin | Buy | 40 000 | Common Stock |
| 2024-02-01 | Jones Erin | Buy | 235 000 | Stock Option (Right to Buy) |
| 2024-02-01 | Economides Vassiliki | Buy | 35 000 | Common Stock |
| INSIDER POWER |
|---|
| 100.00 |
| Last 97 transactions |
| Buy: 5 929 842 | Sell: 139 571 |
Forecast:
16:00 - $0.744
Live Trading Signals (every 1 min)
Forecast
1: 16:00 - $0.744
Forecast 2: 16:00 - $0.744
Forecast 3: 16:00 - $0.744
SCORE
10.00
Buy
10.00
Buy
Score Algorithm Version: 1.2C
Last version updated: Fri April 15th, 2022
Last version updated: Fri April 15th, 2022
| Indicator Signals | |
|---|---|
| RSI 21 | |
| SMA | |
| Trend | |
| Trend 2 | |
| Trend 3 | |
| MACD |
| Volume Signals | |
|---|---|
| Price | $0.744 (-0.20% ) |
| Volume | 2.08 mill |
| Avg. Vol. | 2.91 mill |
| % of Avg. Vol | 71.53 % |
| Signal 1: | |
| Signal 2: |
Today
Last 12 Months
RSI
Last 10 Buy & Sell Signals For GRTS
0 Signals | Accuracy: 0.00% | Accuracy Buy: 0.00% | Accuracy Sell: 0.00%
Avg return buy: 0.00 % | Avg return sell: 0.00 %
$1 invested is now $1.00 or 0.00% since Coming Soon
| Date | Signal | @ | Closed | % | Feb 8 - 15:35 | sell | $2.22 | N/A | Active |
|---|
GRTS
Gritstone bio, Inc., a clinical-stage biotechnology company, engages in developing immunotherapies against multiple cancer types and infectious diseases. Its lead product candidate is GRANITE, a neoantigen-based immunotherapy for the treatment of solid tumors, including metastatic non-small cell lung cancer, as well as gastroesophageal, bladder and microsatellite stable, and colorectal cancers. The company is also developing SLATE, an off-the-shelf immunotherapy candidate for the treatment of common solid tumors comprising metastatic non-small cell lung cancer, colorectal cancer, pancreatic cancer, and shared neoantigen-positive tumors. In addition, it develops CORAL, a SARS-CoV-2 vaccine platform designed to deliver spike and additional SARS-CoV-2 T cell epitopes for protection and broader immunity against SARS-CoV-2 variants; and a therapeutic vaccine candidate designed to treat and cure human immunodeficiency virus (HIV) infection. It has a strategic collaboration with bluebird bio, Inc.; collaboration agreement with Gilead Sciences, Inc.; and license agreement with Genevant Sciences GmbH. The company was formerly known as Gritstone Oncology, Inc. and changed its name to Gritstone bio, Inc. in May 2021. Gritstone bio, Inc. was incorporated in 2015 and is headquartered in Emeryville, California.
Latest Press Releases
2024-04-15 07:00:00 - Press Release
Nature Medicine Publishes Interim Results From Gritstone Bio's Phase 1/2 Study Of “off-the-shelf” Neoantigen Vaccine Platform (slate)
-- paper details vaccine design optimization process of gritstone's “off-the-shelf” or shared neoantigen vaccine platform, slate -- -- discovery of a novel immunodominance hierarchy of tumor neoantigens (including kras) enabled the development of a more potent, kras-specific vaccine candidate (slate-kras) being studied by steven a. rosenberg of the national cancer institute (nci) --
2024-04-12 09:30:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Gritstone Bio, Inc. - Grts
New york , april 12, 2024 /prnewswire/ -- pomerantz llp is investigating claims on behalf of investors of gritstone bio, inc. ("gritstone" or the "company") (nasdaq: grts). such investors are advised to contact danielle peyton at newaction@pomlaw.com or 646-581-9980, ext.
2024-04-04 19:15:00 - Press Release
Shareholder Alert: Pomerantz Law Firm Investigates Claims On Behalf Of Investors Of Gritstone Bio, Inc. - Grts
New york , april 4, 2024 /prnewswire/ -- pomerantz llp is investigating claims on behalf of investors of gritstone bio, inc. ("gritstone" or the "company") (nasdaq: grts). such investors are advised to contact danielle peyton at newaction@pomlaw.com or 646-581-9980, ext.
2024-04-01 23:00:00 - Press Release
Gritstone Bio Announces Pricing Of $32.5 Million Underwritten Public Offering
Emeryville, calif., april 01, 2024 (globe newswire) -- gritstone bio, inc. (nasdaq: grts), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced the pricing of an approximately $32.5 million underwritten public offering of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof), before deducting underwriting discounts and commissions and offering expenses.
2024-04-01 16:10:00 - Press Release
Gritstone Bio Announces Proposed Public Offering
Emeryville, calif., april 01, 2024 (globe newswire) -- gritstone bio, inc. (nasdaq: grts), a clinical-stage biotechnology company working to develop the world's most potent vaccines, today announced that it has commenced an underwritten public offering of shares of its common stock (or pre-funded warrants to purchase common stock in lieu thereof) and accompanying common warrants to purchase common stock (or pre-funded warrants to purchase common stock in lieu thereof). all of the shares of common stock, pre-funded warrants and accompanying common warrants are being offered by gritstone bio. the proposed offering is subject to market and other conditions, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Latest News
2024-04-08 10:35:21 - Zacks Investment Research
Down -63.39% in 4 Weeks, Here's Why Gritstone bio (GRTS) Looks Ripe for a Turnaround
Gritstone bio (GRTS) is technically in oversold territory now, so the heavy selling pressure might have exhausted. This along with strong agreement among Wall Street analysts in raising earnings estimates could lead to a trend reversal for the stock.
2024-04-07 00:22:19 - Seeking Alpha
Gritstone bio: GRANITE Cancer Vaccine Data Overshadowed By Offering
2024-04-04 14:36:06 - Zacks Investment Research
Gritstone (GRTS) Plummets 58% in a Week: Here's Why
Gritstone (GRTS) plunges after a mid-stage study evaluating its personalized cancer vaccine in certain patients with colorectal cancer failed to achieve its primary endpoint.
2024-04-02 09:16:24 - InvestorPlace
Why Is Gritstone Bio (GRTS) Stock Down 44% Today?
Gritstone Bio (NASDAQ: GRTS ) stock is falling on Tuesday after the clinical-stage biotechnology company announced the pricing of an underwritten public offering for its shares. This public offering has the company selling 8,333,333 shares of GRTS stock for $1.50 each.
2024-03-19 14:49:16 - InvestorPlace
3 Speculative Stocks You Can Buy for $3 or Less
The central idea behind cheap speculative stocks under $3 is simple: small-capitalization investments may lever a greater potential for outsized returns. Of course, that depends greatly on the stars aligning perfectly, which rarely happens.
2024-03-05 19:46:03 - Zacks Investment Research
Gritstone bio Inc. (GRTS) Reports Q4 Loss, Tops Revenue Estimates
Gritstone bio Inc. (GRTS) came out with a quarterly loss of $0.26 per share versus the Zacks Consensus Estimate of a loss of $0.36. This compares to loss of $0.30 per share a year ago.
2024-01-31 16:00:00 - InvestorPlace
3 Once-in-a-Lifetime Penny Stocks With Unprecedented Surge Potential
A company's size does not necessarily dictate the size of it's returns. On the contrary, if their jobs are done correctly, these penny stocks with potential can generate exponential returns that will undoubtedly benefit your investments.
2023-10-16 13:32:41 - Zacks Investment Research
Gritstone bio Inc. (GRTS) Upgraded to Buy: What Does It Mean for the Stock?
Gritstone bio Inc. (GRTS) has been upgraded to a Zacks Rank #2 (Buy), reflecting growing optimism about the company's earnings prospects. This might drive the stock higher in the near term.
2023-10-14 02:21:03 - Seeking Alpha
Gritstone bio: Renewed Excitement For Its COVID-19 Vaccine
GRTS's COVID-19 vaccine may produce more durable immunity than current mRNA vaccines, according to data from phase 1 studies. GRTS has secured a $433 million contract with BARDA to conduct a phase 2b study comparing its COVID-19 vaccine with an approved vaccine. GRTS is reporting data from the phase 2/3 GRANITE study of its cancer vaccine in Q1'24.
2023-09-29 11:50:23 - PennyStocks
5 Penny Stocks To Buy According To Analysts, Targets Up To 560%
With the extreme volatility in today's stock market, gaining an edge requires more than just a list of penny stocks to watch. Investors need to leverage the right tools and resources.